1. Phylogeny:  
   Tyrosine‐protein kinase JAK3 belongs to the Janus kinase family, a group of non‐receptor tyrosine kinases that includes JAK1, JAK2, and TYK2. JAK3 is evolutionarily conserved among vertebrates and its gene emerged following gene duplication events that expanded the JAK family from a common ancestral kinase that existed prior to the divergence of invertebrates and vertebrates (yamaoka2004thejanuskinases pages 1-2). In contrast to JAK1, JAK2, and TYK2, which are expressed ubiquitously, JAK3 shows a highly restricted expression profile limited primarily to hematopoietic cells, reflecting its evolution toward a specialized role in immune cell signaling (oshea2009januskinasesin pages 1-2). Phylogenetic analyses demonstrate that the domain architecture (comprising an N-terminal FERM domain, SH2-like module, a pseudokinase (JH2) domain, and a catalytic kinase (JH1) domain) is conserved among JAK family members, although divergence in regulatory elements and expression patterns differentiates JAK3 from its paralogs (babon2014themolecularregulation pages 1-3).
2. Reaction Catalyzed:  
   JAK3 catalyzes a phosphorylation reaction in which ATP donates a phosphate group to specific tyrosine residues on protein substrates, which include the cytoplasmic receptors and downstream signaling proteins such as STAT transcription factors. In chemical terms, the reaction can be summarized as follows: ATP + [protein]-tyrosine → ADP + [protein]-phosphotyrosine + H⁺ (babon2014themolecularregulation pages 3-4).
3. Cofactor Requirements:  
   The catalytic activity of JAK3 depends on the presence of divalent metal cations, and biochemical assays indicate that Mg²⁺ is required as a cofactor to facilitate the ATP-dependent phosphorylation reaction (wu2012januskinase3 pages 2-4).
4. Substrate Specificity:  
   JAK3 preferentially phosphorylates tyrosine residues found in the cytoplasmic domains of cytokine receptors as well as on STAT proteins once they are recruited to these receptor complexes. The specificity of JAK3 is largely dictated by its association with receptors containing the common gamma (γc) chain, thereby catalyzing tyrosine phosphorylation events that facilitate further recruitment and activation of STAT5, among other family members (babon2014themolecularregulation pages 14-15). In addition, recent systematic studies of the human tyrosine kinome have characterized substrate motifs for tyrosine kinases and provide consensus sequence data for tyrosine phosphorylation events, for example showing a preference for motifs that contain specific surrounding amino acid residues such as hydrophobic or basic residues near the target tyrosine (Yaron-Barir2024 pages 1174-1181). Parallel studies in the serine/threonine kinase field indicate that the inherent specificity of kinases is largely determined by the arrangement of neighboring residues, and by analogy, JAK3’s substrate recognition depends on steric and electrostatic complementarity with its substrates (Johnson2023 pages 759-766).
5. Structure:  
   JAK3 is organized into an array of functional domains that coordinate its role in signal transduction. The N-terminal region harbors a FERM domain that is critical for mediating interactions with the intracellular regions of cytokine receptors such as the IL2R, IL7R, and others sharing the γc subunit (yamaoka2004thejanuskinases pages 2-3). Adjacent to the FERM domain, an SH2-like domain contributes to receptor binding and possibly stabilization of the receptor–kinase complex (oshea2009januskinasesin pages 2-4). Central to the protein is the pseudokinase (JH2) domain, which, although catalytically inactive, functions in autoinhibitory regulation and conformational stabilization of the active kinase domain (babon2014themolecularregulation pages 4-6, lupardus2014structureofthe pages 6-6). At the C-terminus, the kinase (JH1) domain is responsible for the catalytic activity of JAK3 and includes features such as the activation loop, a C-helix that participates in the formation of the hydrophobic spine, and the ATP-binding pocket that harbors a unique cysteine residue (Cys909) exploited for covalent inhibitor binding (forster2017recentadvancesin pages 12-16, wu2012januskinase3 pages 5-6). Structural analyses, including crystallography and molecular modeling, reveal that the catalytic domain maintains a bi-lobal architecture common to kinases with key catalytic residues properly aligned to facilitate phosphotransfer (vihinen2000molecularmodelingof pages 5-7). These features, including the N-terminal regulatory domains and the arrangement of the activation loop with regulatory phosphorylatable tyrosine residues, are critical for the proper regulation of JAK3 activity (babon2014themolecularregulation pages 3-4).
6. Regulation:  
   Regulation of JAK3 activity occurs by multiple mechanisms, including post-translational modifications and conformational changes induced by receptor engagement. Autophosphorylation of specific tyrosine residues within the kinase domain, notably in the activation loop, is required for full catalytic activation; for instance, phosphorylation events at positions analogous to Y980 and Y981 in related JAK kinases modulate activity, although detailed mapping in JAK3 continues to emerge (oshea2009januskinasesin pages 6-8). In addition, the pseudokinase domain exerts an autoinhibitory effect under basal conditions by stabilizing the kinase in an inactive conformation (babon2014themolecularregulation pages 4-6). Negative regulatory proteins, such as members of the suppressor of cytokine signaling (SOCS) family and other phosphatases, interact with JAK3 to downregulate its signaling output by promoting dephosphorylation and proteasomal degradation (ungureanu2005posttranslationalmodificationsin pages 11-14). Furthermore, reversible interactions between the FERM and SH2 domains have been reported to modulate substrate access and kinase activation, while covalent modifications via specific inhibitors targeting reactive residues (e.g., covalent binding to Cys909) have provided additional insights into regulatory mechanisms (forster2017recentadvancesin pages 16-18, elwood2017evaluationofjak3 pages 22-24).
7. Function:  
   JAK3 is a non-receptor tyrosine kinase that plays an indispensable role in mediating cytokine receptor signaling in hematopoietic cells. Its primary function involves association with cytokine receptors that share a common gamma (γc) chain, including receptors for interleukins IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21, which are essential for lymphocyte development, proliferation, and survival (babon2014themolecularregulation pages 14-15, oshea2009januskinasesin pages 6-8). Upon ligand binding to these receptors, JAK3 becomes activated by trans-phosphorylation in coordination with JAK1, and subsequently phosphorylates tyrosine residues on the receptor cytoplasmic tails; these phosphorylated sites serve as docking sites for STAT transcription factors (babon2014themolecularregulation pages 13-14, oshea2009januskinasesin pages 20-23). The phosphorylation of STATs, particularly STAT5, allows their dimerization and nuclear translocation where they regulate gene transcription pertinent to immune responses and hematopoiesis (elwood2017evaluationofjak3 pages 5-7). JAK3’s restricted expression to hematopoietic and immune cells underlies its essential role in T-cell development and function, and mutations in JAK3 result in severe combined immunodeficiency (SCID) characterized by impaired T and NK cell maturation (oshea2009januskinasesin pages 6-8, rane2000januskinasescomponents pages 13-14). This central role in immune signaling has motivated the development of selective inhibitors, which aim to modulate aberrant JAK3 activity in autoimmune disorders and some hematologic malignancies (elwood2017evaluationofjak3 pages 22-24, forster2017recentadvancesin pages 18-20).
8. Other Comments:  
   Several small molecule inhibitors targeting JAK3 have been developed with an emphasis on achieving high selectivity over other JAK family members. Notably, covalent inhibitors that specifically modify the unique Cys909 residue in the JAK3 kinase domain have demonstrated both potent and selective inhibition in biochemical and cellular assays (forster2017recentadvancesin pages 20-23, elwood2017evaluationofjak3 pages 29-30). These inhibitors are under clinical evaluation for the treatment of autoimmune diseases such as rheumatoid arthritis, given their potential to suppress pathological cytokine signaling while sparing JAK-mediated hematopoiesis (elwood2017evaluationofjak3 pages 22-24, dymock2013inhibitorsofjak2 pages 35-36). In addition to pharmacological modulation, genetic mutations – both loss-of-function mutations, which lead to SCID, and activating mutations found in leukemias – underscore the critical role of JAK3 in maintaining immune homeostasis (rane2000januskinasescomponents pages 1-2, walters2006activatingallelesof pages 1-2). Ongoing research into the substrate specificity and regulatory mechanisms of JAK3, integrating findings from studies on the intrinsic specificity of the human tyrosine kinome (Yaron-Barir2024) and comparative kinase specificity profiling (Johnson2023), continues to refine our understanding of its role in cellular signaling and therapeutic targeting.
9. References:  
   babon2014themolecularregulation pages 1-3; babon2014themolecularregulation pages 3-4; babon2014themolecularregulation pages 13-14; babon2014themolecularregulation pages 14-15; dymock2013inhibitorsofjak2 pages 35-36; elwood2017evaluationofjak3 pages 5-7; elwood2017evaluationofjak3 pages 7-8; elwood2017evaluationofjak3 pages 20-22; elwood2017evaluationofjak3 pages 29-30; forster2017recentadvancesin pages 12-16; forster2017recentadvancesin pages 16-18; forster2017recentadvancesin pages 18-20; forster2017recentadvancesin pages 20-23; lupardus2014structureofthe pages 1-2; lupardus2014structureofthe pages 5-6; lupardus2014structureofthe pages 6-6; mishra2017januskinase3 pages 1-2; oshea2009januskinasesin pages 1-2; oshea2009januskinasesin pages 2-4; oshea2009januskinasesin pages 6-8; oshea2009januskinasesin pages 20-23; rane2000januskinasescomponents pages 1-2; rane2000januskinasescomponents pages 13-14; ungureanu2005posttranslationalmodificationsin pages 11-14; ungureanu2005posttranslationalmodificationsin pages 14-16; vihinen2000molecularmodelingof pages 5-7; vihinen2000molecularmodelingof pages 7-9; wang2013theroleof pages 8-10; wu2012januskinase3 pages 1-2; wu2012januskinase3 pages 2-4; wu2012januskinase3 pages 5-6; wu2012januskinase3 pages 8-9; yamaoka2004thejanuskinases pages 1-2; yamaoka2004thejanuskinases pages 2-3; yamaoka2004thejanuskinases pages 3-4; Johnson2023; Yaron-Barir2024

References

1. (babon2014themolecularregulation pages 13-14): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
2. (babon2014themolecularregulation pages 14-15): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
3. (babon2014themolecularregulation pages 4-6): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
4. (elwood2017evaluationofjak3 pages 22-24): Fiona Elwood, David J. Witter, Jennifer Piesvaux, Brian Kraybill, Nathan Bays, Carla Alpert, Peter Goldenblatt, Yujie Qu, Irena Ivanovska, Hyun-Hee Lee, Chi-Sung Chiu, Hao Tang, Mark E. Scott, Sujal V. Deshmukh, Mark Zielstorff, Alan Byford, Kalyan Chakravarthy, Lauren Dorosh, Alexey Rivkin, Joel Klappenbach, Bo-Sheng Pan, Ilona Kariv, Christopher Dinsmore, Deborah Slipetz, and Peter J. Dandliker. Evaluation of jak3 biology in autoimmune disease using a highly selective, irreversible jak3 inhibitor. The Journal of Pharmacology and Experimental Therapeutics, 361:229-244, May 2017. URL: https://doi.org/10.1124/jpet.116.239723, doi:10.1124/jpet.116.239723. This article has 32 citations.
5. (forster2017recentadvancesin pages 12-16): Michael Forster, Matthias Gehringer, and Stefan A. Laufer. Recent advances in jak3 inhibition: isoform selectivity by covalent cysteine targeting. Bioorganic & Medicinal Chemistry Letters, 27:4229-4237, Sep 2017. URL: https://doi.org/10.1016/j.bmcl.2017.07.079, doi:10.1016/j.bmcl.2017.07.079. This article has 39 citations.
6. (forster2017recentadvancesin pages 16-18): Michael Forster, Matthias Gehringer, and Stefan A. Laufer. Recent advances in jak3 inhibition: isoform selectivity by covalent cysteine targeting. Bioorganic & Medicinal Chemistry Letters, 27:4229-4237, Sep 2017. URL: https://doi.org/10.1016/j.bmcl.2017.07.079, doi:10.1016/j.bmcl.2017.07.079. This article has 39 citations.
7. (lupardus2014structureofthe pages 1-2): Patrick J. Lupardus, Mark Ultsch, Heidi Wallweber, Pawan Bir Kohli, Adam R. Johnson, and Charles Eigenbrot. Structure of the pseudokinase–kinase domains from protein kinase tyk2 reveals a mechanism for janus kinase (jak) autoinhibition. Proceedings of the National Academy of Sciences, 111:8025-8030, May 2014. URL: https://doi.org/10.1073/pnas.1401180111, doi:10.1073/pnas.1401180111. This article has 226 citations.
8. (lupardus2014structureofthe pages 6-6): Patrick J. Lupardus, Mark Ultsch, Heidi Wallweber, Pawan Bir Kohli, Adam R. Johnson, and Charles Eigenbrot. Structure of the pseudokinase–kinase domains from protein kinase tyk2 reveals a mechanism for janus kinase (jak) autoinhibition. Proceedings of the National Academy of Sciences, 111:8025-8030, May 2014. URL: https://doi.org/10.1073/pnas.1401180111, doi:10.1073/pnas.1401180111. This article has 226 citations.
9. (oshea2009januskinasesin pages 2-4): JJ O’Shea. Janus kinases in immune cell signaling. Unknown journal, 2009. URL: https://doi.org/10.1111/j.1600-065x.2008.00754, doi:10.1111/j.1600-065x.2008.00754.
10. (rane2000januskinasescomponents pages 1-2): Sushil G Rane and E Premkumar Reddy. Janus kinases: components of multiple signaling pathways. Oncogene, 19:5662-5679, Nov 2000. URL: https://doi.org/10.1038/sj.onc.1203925, doi:10.1038/sj.onc.1203925. This article has 648 citations and is from a domain leading peer-reviewed journal.
11. (rane2000januskinasescomponents pages 13-14): Sushil G Rane and E Premkumar Reddy. Janus kinases: components of multiple signaling pathways. Oncogene, 19:5662-5679, Nov 2000. URL: https://doi.org/10.1038/sj.onc.1203925, doi:10.1038/sj.onc.1203925. This article has 648 citations and is from a domain leading peer-reviewed journal.
12. (ungureanu2005posttranslationalmodificationsin pages 11-14): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
13. (ungureanu2005posttranslationalmodificationsin pages 14-16): D Ungureanu. Post-translational modifications in regulation of jak-stat pathway. Unknown journal, 2005.
14. (vihinen2000molecularmodelingof pages 5-7): Mauno Vihinen, Anna Villa, Patrizia Mella, R.Fabian Schumacher, Gianfranco Savoldi, John J. O’Shea, Fabio Candotti, and Luigi D. Notarangelo. Molecular modeling of the jak3 kinase domains and structural basis for severe combined immunodeficiency. Clinical Immunology, 96:108-118, Aug 2000. URL: https://doi.org/10.1006/clim.2000.4880, doi:10.1006/clim.2000.4880. This article has 36 citations and is from a peer-reviewed journal.
15. (vihinen2000molecularmodelingof pages 7-9): Mauno Vihinen, Anna Villa, Patrizia Mella, R.Fabian Schumacher, Gianfranco Savoldi, John J. O’Shea, Fabio Candotti, and Luigi D. Notarangelo. Molecular modeling of the jak3 kinase domains and structural basis for severe combined immunodeficiency. Clinical Immunology, 96:108-118, Aug 2000. URL: https://doi.org/10.1006/clim.2000.4880, doi:10.1006/clim.2000.4880. This article has 36 citations and is from a peer-reviewed journal.
16. (walters2006activatingallelesof pages 1-2): Denise K. Walters, Thomas Mercher, Ting-Lei Gu, Thomas O’Hare, Jeffrey W. Tyner, Marc Loriaux, Valerie L. Goss, Kimberly A. Lee, Christopher A. Eide, Matthew J. Wong, Eric P. Stoffregen, Laura McGreevey, Julie Nardone, Sandra A. Moore, John Crispino, Titus J. Boggon, Michael C. Heinrich, Michael W. Deininger, Roberto D. Polakiewicz, D. Gary Gilliland, and Brian J. Druker. Activating alleles of jak3 in acute megakaryoblastic leukemia. Cancer Cell, 10:65-75, Jul 2006. URL: https://doi.org/10.1016/j.ccr.2006.06.002, doi:10.1016/j.ccr.2006.06.002. This article has 369 citations and is from a highest quality peer-reviewed journal.
17. (wang2013theroleof pages 8-10): Huizhi Wang, Jonathan Brown, Shegan Gao, Shuang Liang, Ravi Jotwani, Huaxin Zhou, Jill Suttles, David A Scott, and Richard J Lamont. The role of jak-3 in regulating tlr-mediated inflammatory cytokine production in innate immune cells. The Journal of Immunology, 191:1164-1174, Aug 2013. URL: https://doi.org/10.4049/jimmunol.1203084, doi:10.4049/jimmunol.1203084. This article has 75 citations.
18. (wu2012januskinase3 pages 1-2): Wei Wu and Xiao-Hong Sun. Janus kinase 3: the controller and the controlled. Acta Biochimica et Biophysica Sinica, 44:187-196, Mar 2012. URL: https://doi.org/10.1093/abbs/gmr105, doi:10.1093/abbs/gmr105. This article has 37 citations and is from a peer-reviewed journal.
19. (wu2012januskinase3 pages 2-4): Wei Wu and Xiao-Hong Sun. Janus kinase 3: the controller and the controlled. Acta Biochimica et Biophysica Sinica, 44:187-196, Mar 2012. URL: https://doi.org/10.1093/abbs/gmr105, doi:10.1093/abbs/gmr105. This article has 37 citations and is from a peer-reviewed journal.
20. (wu2012januskinase3 pages 5-6): Wei Wu and Xiao-Hong Sun. Janus kinase 3: the controller and the controlled. Acta Biochimica et Biophysica Sinica, 44:187-196, Mar 2012. URL: https://doi.org/10.1093/abbs/gmr105, doi:10.1093/abbs/gmr105. This article has 37 citations and is from a peer-reviewed journal.
21. (wu2012januskinase3 pages 8-9): Wei Wu and Xiao-Hong Sun. Janus kinase 3: the controller and the controlled. Acta Biochimica et Biophysica Sinica, 44:187-196, Mar 2012. URL: https://doi.org/10.1093/abbs/gmr105, doi:10.1093/abbs/gmr105. This article has 37 citations and is from a peer-reviewed journal.
22. (yamaoka2004thejanuskinases pages 1-2): Kunihiro Yamaoka, Pipsa Saharinen, Marko Pesu, Vance ET Holt, Olli Silvennoinen, and John J O’Shea. The janus kinases (jaks). Genome Biology, 5:253-253, Nov 2004. URL: https://doi.org/10.1186/gb-2004-5-12-253, doi:10.1186/gb-2004-5-12-253. This article has 840 citations and is from a highest quality peer-reviewed journal.
23. (yamaoka2004thejanuskinases pages 2-3): Kunihiro Yamaoka, Pipsa Saharinen, Marko Pesu, Vance ET Holt, Olli Silvennoinen, and John J O’Shea. The janus kinases (jaks). Genome Biology, 5:253-253, Nov 2004. URL: https://doi.org/10.1186/gb-2004-5-12-253, doi:10.1186/gb-2004-5-12-253. This article has 840 citations and is from a highest quality peer-reviewed journal.
24. (yamaoka2004thejanuskinases pages 3-4): Kunihiro Yamaoka, Pipsa Saharinen, Marko Pesu, Vance ET Holt, Olli Silvennoinen, and John J O’Shea. The janus kinases (jaks). Genome Biology, 5:253-253, Nov 2004. URL: https://doi.org/10.1186/gb-2004-5-12-253, doi:10.1186/gb-2004-5-12-253. This article has 840 citations and is from a highest quality peer-reviewed journal.
25. (babon2014themolecularregulation pages 1-3): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
26. (babon2014themolecularregulation pages 3-4): Jeffrey J. Babon, Isabelle S. Lucet, James M. Murphy, Nicos A. Nicola, and Leila N. Varghese. The molecular regulation of janus kinase (jak) activation. The Biochemical journal, 462 1:1-13, Aug 2014. URL: https://doi.org/10.1042/bj20140712, doi:10.1042/bj20140712. This article has 410 citations.
27. (dymock2013inhibitorsofjak2 pages 35-36): Brian W Dymock and Cheng Shang See. Inhibitors of jak2 and jak3: an update on the patent literature 2010 – 2012. Expert Opinion on Therapeutic Patents, 23:449-501, Mar 2013. URL: https://doi.org/10.1517/13543776.2013.765862, doi:10.1517/13543776.2013.765862. This article has 51 citations and is from a peer-reviewed journal.
28. (elwood2017evaluationofjak3 pages 20-22): Fiona Elwood, David J. Witter, Jennifer Piesvaux, Brian Kraybill, Nathan Bays, Carla Alpert, Peter Goldenblatt, Yujie Qu, Irena Ivanovska, Hyun-Hee Lee, Chi-Sung Chiu, Hao Tang, Mark E. Scott, Sujal V. Deshmukh, Mark Zielstorff, Alan Byford, Kalyan Chakravarthy, Lauren Dorosh, Alexey Rivkin, Joel Klappenbach, Bo-Sheng Pan, Ilona Kariv, Christopher Dinsmore, Deborah Slipetz, and Peter J. Dandliker. Evaluation of jak3 biology in autoimmune disease using a highly selective, irreversible jak3 inhibitor. The Journal of Pharmacology and Experimental Therapeutics, 361:229-244, May 2017. URL: https://doi.org/10.1124/jpet.116.239723, doi:10.1124/jpet.116.239723. This article has 32 citations.
29. (elwood2017evaluationofjak3 pages 29-30): Fiona Elwood, David J. Witter, Jennifer Piesvaux, Brian Kraybill, Nathan Bays, Carla Alpert, Peter Goldenblatt, Yujie Qu, Irena Ivanovska, Hyun-Hee Lee, Chi-Sung Chiu, Hao Tang, Mark E. Scott, Sujal V. Deshmukh, Mark Zielstorff, Alan Byford, Kalyan Chakravarthy, Lauren Dorosh, Alexey Rivkin, Joel Klappenbach, Bo-Sheng Pan, Ilona Kariv, Christopher Dinsmore, Deborah Slipetz, and Peter J. Dandliker. Evaluation of jak3 biology in autoimmune disease using a highly selective, irreversible jak3 inhibitor. The Journal of Pharmacology and Experimental Therapeutics, 361:229-244, May 2017. URL: https://doi.org/10.1124/jpet.116.239723, doi:10.1124/jpet.116.239723. This article has 32 citations.
30. (elwood2017evaluationofjak3 pages 5-7): Fiona Elwood, David J. Witter, Jennifer Piesvaux, Brian Kraybill, Nathan Bays, Carla Alpert, Peter Goldenblatt, Yujie Qu, Irena Ivanovska, Hyun-Hee Lee, Chi-Sung Chiu, Hao Tang, Mark E. Scott, Sujal V. Deshmukh, Mark Zielstorff, Alan Byford, Kalyan Chakravarthy, Lauren Dorosh, Alexey Rivkin, Joel Klappenbach, Bo-Sheng Pan, Ilona Kariv, Christopher Dinsmore, Deborah Slipetz, and Peter J. Dandliker. Evaluation of jak3 biology in autoimmune disease using a highly selective, irreversible jak3 inhibitor. The Journal of Pharmacology and Experimental Therapeutics, 361:229-244, May 2017. URL: https://doi.org/10.1124/jpet.116.239723, doi:10.1124/jpet.116.239723. This article has 32 citations.
31. (elwood2017evaluationofjak3 pages 7-8): Fiona Elwood, David J. Witter, Jennifer Piesvaux, Brian Kraybill, Nathan Bays, Carla Alpert, Peter Goldenblatt, Yujie Qu, Irena Ivanovska, Hyun-Hee Lee, Chi-Sung Chiu, Hao Tang, Mark E. Scott, Sujal V. Deshmukh, Mark Zielstorff, Alan Byford, Kalyan Chakravarthy, Lauren Dorosh, Alexey Rivkin, Joel Klappenbach, Bo-Sheng Pan, Ilona Kariv, Christopher Dinsmore, Deborah Slipetz, and Peter J. Dandliker. Evaluation of jak3 biology in autoimmune disease using a highly selective, irreversible jak3 inhibitor. The Journal of Pharmacology and Experimental Therapeutics, 361:229-244, May 2017. URL: https://doi.org/10.1124/jpet.116.239723, doi:10.1124/jpet.116.239723. This article has 32 citations.
32. (forster2017recentadvancesin pages 18-20): Michael Forster, Matthias Gehringer, and Stefan A. Laufer. Recent advances in jak3 inhibition: isoform selectivity by covalent cysteine targeting. Bioorganic & Medicinal Chemistry Letters, 27:4229-4237, Sep 2017. URL: https://doi.org/10.1016/j.bmcl.2017.07.079, doi:10.1016/j.bmcl.2017.07.079. This article has 39 citations.
33. (forster2017recentadvancesin pages 20-23): Michael Forster, Matthias Gehringer, and Stefan A. Laufer. Recent advances in jak3 inhibition: isoform selectivity by covalent cysteine targeting. Bioorganic & Medicinal Chemistry Letters, 27:4229-4237, Sep 2017. URL: https://doi.org/10.1016/j.bmcl.2017.07.079, doi:10.1016/j.bmcl.2017.07.079. This article has 39 citations.
34. (lupardus2014structureofthe pages 5-6): Patrick J. Lupardus, Mark Ultsch, Heidi Wallweber, Pawan Bir Kohli, Adam R. Johnson, and Charles Eigenbrot. Structure of the pseudokinase–kinase domains from protein kinase tyk2 reveals a mechanism for janus kinase (jak) autoinhibition. Proceedings of the National Academy of Sciences, 111:8025-8030, May 2014. URL: https://doi.org/10.1073/pnas.1401180111, doi:10.1073/pnas.1401180111. This article has 226 citations.
35. (mishra2017januskinase3 pages 1-2): Jayshree Mishra, Jugal Kishore Das, and Narendra Kumar. Janus kinase 3 regulates adherens junctions and epithelial mesenchymal transition through β-catenin. Journal of Biological Chemistry, 292:16406-16419, Oct 2017. URL: https://doi.org/10.1074/jbc.m117.811802, doi:10.1074/jbc.m117.811802. This article has 26 citations and is from a domain leading peer-reviewed journal.
36. (oshea2009januskinasesin pages 1-2): JJ O’Shea. Janus kinases in immune cell signaling. Unknown journal, 2009. URL: https://doi.org/10.1111/j.1600-065x.2008.00754, doi:10.1111/j.1600-065x.2008.00754.
37. (oshea2009januskinasesin pages 20-23): JJ O’Shea. Janus kinases in immune cell signaling. Unknown journal, 2009. URL: https://doi.org/10.1111/j.1600-065x.2008.00754, doi:10.1111/j.1600-065x.2008.00754.
38. (oshea2009januskinasesin pages 6-8): JJ O’Shea. Janus kinases in immune cell signaling. Unknown journal, 2009. URL: https://doi.org/10.1111/j.1600-065x.2008.00754, doi:10.1111/j.1600-065x.2008.00754.